A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00502138
Recruitment Status : Completed
First Posted : July 17, 2007
Last Update Posted : January 16, 2013
Amylin Pharmaceuticals, LLC.
Information provided by (Responsible Party):
David M. Huffman MD, University Diabetes & Endocrine Consultants

Brief Summary:
This research project will investigate the effects of pramlintide (Symlin) given by continuous subcutaneous (under the skin) infusion throughout the day and night, along with meal doses similar to those injected during conventional pramlintide (Symlin) treatment, delivered using a second insulin pump, in subjects with inadequately controlled type I diabetes mellitus who are already using insulin pump therapy. Study participants will wear two pumps for a four month period, taking insulin in their usual manner and pramlintide (Symlin) in a similar basal/bolus fashion. Continuous glucose monitors will be worn on three occasions during the study to assess blood glucose responses to continuous pramlintide (Symlin) treatment.

Condition or disease Intervention/treatment Phase
IDDM Drug: Continuous Pramlintide infusion Phase 4

Detailed Description:


To participate in the study, you must have Type I diabetes mellitus and be taking insulin using an insulin pump, and have a hemoglobin A1c level between 7.0% and 10.0%. You will not be permitted to participate in the study if you have taken pramlintide (Symlin) during the previous three months. The study will consist of seven visits to the Study Center over a four-month period. Subjects will undergo meal tolerance testing at beginning and end of study period. Continuous blood glucose monitoring will be performed on three occasions during the study.

Pramlintide will be begun at a single basal rate of 1.5 units/hr. Bolus therapy will be begun thereafter per standard manufacturer protocol. Subjects will be monitored for three months on basal-bolus pramlintide therapy.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Pramlintide Acetate When Administered by Subcutaneous Infusion in a Basal-Bolus Manner as an Adjunct to Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes
Study Start Date : July 2007
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
U.S. FDA Resources

Arm Intervention/treatment
Experimental: A
Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion
Drug: Continuous Pramlintide infusion
pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
Other Name: pramlintide

Primary Outcome Measures :
  1. Fasting and postprandial pramlintide pharmacokinetics [ Time Frame: Four months ]

Secondary Outcome Measures :
  1. Hemoglobin A1c, body weight, blood glucose variability, patient satisfaction [ Time Frame: four months ]
  2. Hemoglobin A1c [ Time Frame: 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Type 1 diabetes of at least one year duration;
  2. Treated with CSII therapy for at least 6 months;
  3. Age 18 to 70 years, inclusive;
  4. A1C >7.0 and ≤10% as screening;
  5. BMI ≤35 kg/m2;
  6. Stable insulin dose (±10%) for at least 3 months prior to screening;
  7. If female, has a negative urine pregnancy test at screening;
  8. If female and of childbearing potential, practicing and willing to continue to using appropriate contraception to ensure that pregnancy does not occur during the study;
  9. Able to understand and sign the required study documents and comply with the protocol requirements

Exclusion Criteria:

  1. Is poorly compliant with the currently prescribed insulin regimen, as determined by the investigator;
  2. Has any significant medical condition, laboratory findings, or medical history that may affect successful completion of the study and/or personal well-being;
  3. If female and if of childbearing potential, is pregnant, lactating, or planning to become pregnant;
  4. Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months;
  5. Has a history of hypoglycemia unawareness;
  6. Has a confirmed diagnosis of gastroparesis;
  7. Requires the use of drugs that stimulate gastrointestinal motility;
  8. Is receiving medications known to interfere with glycemic control (i.e. glucocorticoids);
  9. Has been treated with any oral antidiabetic agent or exenatide within 3 months of screening visit;
  10. Has been treated with pramlintide within 3 months of screening visit;
  11. Has received an investigational drug within 3 month of screening visit;
  12. Is currently participating in a clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00502138

United States, Tennessee
University Diabetes & Endocrine Consultants
Chattanooga, Tennessee, United States, 37403
Sponsors and Collaborators
University Diabetes & Endocrine Consultants
Amylin Pharmaceuticals, LLC.
Principal Investigator: David M Huffman, MD University Diabetes & Endocrine Consultants

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: David M. Huffman MD, Principal Investigator, University Diabetes & Endocrine Consultants Identifier: NCT00502138     History of Changes
Other Study ID Numbers: Pramlintide Infusion in IDDM
First Posted: July 17, 2007    Key Record Dates
Last Update Posted: January 16, 2013
Last Verified: January 2013

Keywords provided by David M. Huffman MD, University Diabetes & Endocrine Consultants:

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Islet Amyloid Polypeptide
Hypoglycemic Agents
Physiological Effects of Drugs
Appetite Depressants
Anti-Obesity Agents
Amylin Receptor Agonists
Molecular Mechanisms of Pharmacological Action